Phase 2Completed
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.
- Sponsor
- Solvay Pharmaceuticals (Industry)
- Enrollment
- 2,288 enrolled
- Conditions
- Patients With Metabolic Syndrome
- Interventions
- Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Placebo
- Ages
- adults, older adults
- Registry
- NCT00703755
Full record on ClinicalTrials.gov
From the registry
The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing normalization of MetS patients.
Primary outcomes
- The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)
History
Last registry update
Registered
Primary completion
Started